All the evidence for the necroptotic agents in AD treatment comes from animal studies, and no human clinical trials are being conducted Similarly, the evidence of these agents upon the MT network, as a result of their effect upon hyperphosphorylated tau protein and Aβ, is still missing. This evidence concerns the gene MAPT and Alzheimer disease.